Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan.
Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan;
Anticancer Res. 2022 May;42(5):2775-2782. doi: 10.21873/anticanres.15757.
BACKGROUND/AIM: Esophageal squamous cell carcinoma (ESCC) is a deadly malignant disease. This study examined whether the platelet-to-lymphocyte ratio (PLR) can be used as a biomarker to evaluate prognosis in patients with advanced ESCC following neoadjuvant chemotherapy (NAC) and undergoing minimally invasive esophagectomy (MIE).
We examined 174 patients between January 2010 and December 2015 at the Kobe University. Of these, 121 were treated with NAC. The PLR cutoff was determined through receiver-operating characteristic curve analysis. Univariate and multivariate analyses were conducted to identify prognostic factors for overall survival (OS).
The PLR cutoff for OS in 121 patients was 169.6. Patients with PLR ≥169.6 had worse 5-year OS rates (31.1%) than those with a PLR <169.6 (61.1%, p=0.001). Multivariate analysis revealed that a PLR of ≥169.6 was an independent factor for poor prognosis.
PLR is an independent prognostic factor for patients with ESCC after NAC and MIE.
背景/目的：食管鳞状细胞癌（ESCC）是一种致命的恶性疾病。本研究旨在探讨血小板与淋巴细胞比值（PLR）能否作为评估接受新辅助化疗（NAC）和微创食管切除术（MIE）的晚期 ESCC 患者预后的生物标志物。
我们回顾了 2010 年 1 月至 2015 年 12 月在神户大学接受治疗的 174 名患者，其中 121 名患者接受了 NAC 治疗。通过接受者操作特征曲线分析确定 PLR 截断值。进行单因素和多因素分析以确定总生存期（OS）的预后因素。
121 名患者的 OS 的 PLR 截断值为 169.6。PLR≥169.6 的患者 5 年 OS 率（31.1%）明显低于 PLR＜169.6 的患者（61.1%，p=0.001）。多因素分析显示，PLR≥169.6 是预后不良的独立因素。
PLR 是接受 NAC 和 MIE 治疗后的 ESCC 患者的独立预后因素。
